Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India

Gupta, Ruta; Seethalakshmi, V.; Jambhekar, Nirmala A.; Prabhudesai, Shilpa; Merchant, Nikhil H.; Puri, Ajay; Agarwal, Manish

doi:10.1016/j.anndiagpath.2007.09.002

Cited by 89 publications

(89 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A second limitation is that although stringent radiographic criteria have been used to identify metastases, not all lesions were histologically verified. However, this series includes all radiographically detected operable and inoperable metastatic lesions in contrast to other reported series of the same subject [7,9,17,19,20]. Many of the inoperable patients were treated symptomatically and therefore were followed up over the natural course of these presumed metastatic lesions.…”

Section: Discussionmentioning

confidence: 98%

“…GCTs of bone are regarded as aggressive and the most unpredictable neoplasms of the skeletal system, which can metastasize despite their innocent appearance [7,9,17,19,20]. There currently is no definitive method of predicting distant metastasis in GCT based on histology or flow cytometry [12].…”

Section: Discussionmentioning

confidence: 99%

“…There currently is no definitive method of predicting distant metastasis in GCT based on histology or flow cytometry [12]. We therefore explored the association, if any, between variably reported factors with metastasis in GCT [7,9,17,19,20], such as site of primary tumor, duration and number of local recurrences, and treatment of primary tumor, assessed their outcome after a long followup, and evaluated the optimum therapeutic modality for management.…”

Section: Discussionmentioning

confidence: 99%

“…Metastasis in giant cell tumor (GCT) of bone occurs most commonly in the lung, variously reported from 1% to 9% [7,9,17,19,20]. There have been isolated case reports of its occurrence at different sites, such as the lymph nodes (mediastinum, paraaortic), bone, skin, and breast [1,6,9,13,14,21].…”

Section: Introductionmentioning

confidence: 99%

“…There have been isolated case reports of its occurrence at different sites, such as the lymph nodes (mediastinum, paraaortic), bone, skin, and breast [1,6,9,13,14,21]. However, awareness of the metastatic potential of these tumors has increased, and improved methods of detection have led to their increased recognition [9].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Metastatic Giant Cell Tumor of Bone: Are There Associated Factors and Best Treatment Modalities?

Viswanathan

Jambhekar

2010

Clinical Orthopaedics &Amp; Related Research

112

View full text Add to dashboard Cite

Giant cell tumors of bone are sometimes locally aggressive and may metastasize, although uncommonly. We attempted to identify associations of clinical and histopathologic parameters with metastasis, the longterm outcome with metastases, and the best treatment. We identified distant metastases in 24 of 470 patients with giant cell tumors during a 20-year period. The median age of these 24 patients at presentation was 26 years (range, 16-76 years), and the male:female ratio was 1.6:1, with no predilection for primary site. Metastasis occurred at a mean of 2 years (range, 4 months-11 years) after initial diagnosis. Sites for distant metastases were the lung (21 of 24 patients), scalp, calf muscle, and regional lymph nodes. The 24 patients had a mean followup of 3.5 years (range, 0-16 years

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Metastatic Giant Cell Tumor of Bone: Are There Associated Factors and Best Treatment Modalities?

Viswanathan

Jambhekar

2010

Clinical Orthopaedics &Amp; Related Research

112

View full text Add to dashboard Cite

show abstract

Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis

Baud’huin

Renault

Charrier

et al. 2010

The Journal of Pathology

141

View full text Add to dashboard Cite

Interleukin-34 (IL-34) is a newly discovered regulator of myeloid lineage differentiation, proliferation, and survival, acting via the macrophage-colony stimulating factor receptor (M-CSF receptor, c-fms). M-CSF, the main ligand for c-fms, is required for osteoclastogenesis and has been already identified as a critical contributor of the pathogenesis of giant cell tumours of bone (GCTs), tumours rich in osteoclasts. According to the key role of M-CSF in osteoclastogenesis and GCTs, the expression of IL-34 in human GCTs was first assessed. Quantitative analysis of IL-34 mRNA expression in 14 human GCTs revealed expression of this cytokine in GCTs as well as M-CSF and c-fms. Immunohistochemistry demonstrated that osteoclast-like cells exhibited a huge immunostaining for IL-34 and that mononuclear stromal cells were slightly positive for this protein. In contrast to osteoblasts, bone-resorbing osteoclasts showed very strong staining for IL-34, suggesting its potential role in the pathogenesis of GCTs by facilitating osteoclast formation. The role of IL-34 in osteoclastogenesis was then studied in murine and human models. IL-34 was able to support RANKL-induced osteoclastogenesis in the absence of M-CSF in all models. Multinucleated cells generated in the presence of IL-34 and RANKL expressed specific osteoclastic markers and resorbed dentine. IL-34 induced phosphorylation of ERK 1/2 and Akt through the activation of c-fms, as revealed by the inhibition of signalling by a specific c-fms tyrosine kinase inhibitor. Furthermore, IL-34 stimulated RANKL-induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors, and had no effect on osteoclast survival. Overall, these data reveal that IL-34 can be entirely substituted for M-CSF in RANKL-induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs.

show abstract

Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review

Yayan

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India

Cited by 89 publications

References 30 publications

Metastatic Giant Cell Tumor of Bone: Are There Associated Factors and Best Treatment Modalities?

Metastatic Giant Cell Tumor of Bone: Are There Associated Factors and Best Treatment Modalities?

Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis

Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review

Contact Info

Product

Resources

About